Ownership Submission
|
FORM 4
|
|
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
OMB APPROVAL
|
|
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
|
1. Name and Address of Reporting Person *
|
|
Orozco Tomas
|
|
2. Issuer Name and Ticker or Trading Symbol
NeueHealth, Inc. [NEUE]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
_____ Director
|
_____ 10% Owner
|
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
EVP, Consumer Care /
|
|
|
(Last)
|
(First)
|
(Middle)
|
|
8000 NORMAN CENTER DRIVE , SUITE 900
|
|
3. Date of Earliest Transaction (Month/Day/Year)
|
(Street)
|
|
MINNEAPOLIS
|
MN
|
55437
|
|
4. If Amendment, Date Original Filed(Month/Day/Year)
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
|
1.Title of Security
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code
|
4. Securities Acquired (A) or Disposed of (D)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
|
6. Ownership Form: Direct (D) or Indirect (I)
|
7. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
|
8. Price of Derivative Security
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
11. Nature of Indirect Beneficial Ownership
|
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
|
Director
|
10% Owner
|
Officer
|
Other
|
Orozco Tomas
8000 NORMAN CENTER DRIVE
SUITE 900
MINNEAPOLIS, MN55437
|
|
|
EVP, Consumer Care
|
|
Signatures
|
/s/ Eric Halverson for Tomas Orozco, Attorney-in-Fact
|
2024-05-06
|
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
|
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
|
(1)
|
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
|
|
(2)
|
This grant was approved on March 11, 2024 by the Issuer's Compensation and Human Capital Committee as part of the Issuer's annual equity grants, subject to shareholder approval of an amendment to the Issuer's Amended and Restated 2021 Omnibus Incentive Plan, which approval was obtained on May 2, 2024.
|
|
(3)
|
These restricted stock units vest in three equal annual installments beginning on March 11, 2025.
|
|
(4)
|
This grant was approved on October 11, 2023 by the Issuer's Compensation and Human Capital Committee, subject to shareholder approval of an amendment to the Issuer's Amended and Restated 2021 Omnibus Incentive Plan, which approval was obtained on May 2, 2024.
|
|
(5)
|
100% of these restricted stock units vest on October 11, 2026.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
